PDCD1 and neoplasm: Patients with high baseline PD-L1 expression on circulating tumor cells (CTCs) who received anti-PD-1/PD-L1 monoclonal antibodies combined with conventional chemotherapy regimens showed significantly prolonged progression-free survival (median PFS: 4.9 months vs. 2.2 months, P < 0.0001) (52).